ExpreS2ion Biotech: Finalized terms of SEK53m rights issue - Redeye
Bildkälla: Stockfoto

ExpreS2ion Biotech: Finalized terms of SEK53m rights issue - Redeye

Redeye comments on ExpreS2ion’s finalized rights issue of approximately SEK53m, including free-of-charge TO13 warrants, aimed at funding completion of the ES2B-C001 phase I program and supporting platform development. While the financing significantly strengthens the company’s runway, the substantial dilution relative to our prior assumptions weighs heavy on our per share valuation.

Redeye comments on ExpreS2ion’s finalized rights issue of approximately SEK53m, including free-of-charge TO13 warrants, aimed at funding completion of the ES2B-C001 phase I program and supporting platform development. While the financing significantly strengthens the company’s runway, the substantial dilution relative to our prior assumptions weighs heavy on our per share valuation.
Börsvärldens nyhetsbrev